A single, comprehensive resource on the biomarkers that are actively being
researched or used in all major therapeutic areas, BIOMARKERcenter
it is the first biomarker database to provide standardized terminology, and
to classify biomarkers reliably into life cycle phases and disciplines.
BIOMARKERcenter is reliable in content, rich in analysis, and backed
up by rigorous editorial standards and the best possible customer service. It
can show you exactly how much trust you can put in the biomarker data you rely
on to support your stage gate decisions and plan and execute your clinical trials.
It is available as a subscription option to users of Prous Science Integrity®.
The data is also available as an XML feed for your in-house bioinformatics solutions.
|
|
 |
Discovery biologists: BIOMARKERcenter can help you
to learn the biology of the disease you’re working on, and to understand the
current state of the art regarding biomarkers in your therapy area. You can
choose the biomarker that will give early indications on whether modifying a
potential new target will have a positive outcome on the disease process.
Preclinical scientists: BIOMARKERcenter can help
you to find the biomarkers that show the effects of your compound on the disease
state. By returning all the biomarkers reported for the disease in question,
you can select those which are suitable, saving time in new biomarker research.
Clinical trials managers: BIOMARKERcenter can help
you to find the population that will respond best to the particular treatment.
Knowing which biomarkers to use can improve the design and efficiency of your
studies, and improve your probability of success. |
|
|
|
Covers the biomarkers identified in literature, patents, conferences, medical
meetings and other sources for all the key therapy areas: oncology, cardiovascular,
metabolism, respiratory, autoimmunology and neurology.
Includes not only biomarkers with established commercial presence but also high
potential biomarkers as identified by industry and academia experts.
Places its wealth of knowledge in context, including related literature, patents,
genomics/targets, drugs and biologics, companies or research institutions, toxicology
and clinical studies, enabling you to assess the relative importance of each
biomarker.
Monitors the lifecycle status of the biomarker from discovery to outcome —a
pipeline approach that answers at a glance the question of trustworthiness,
while providing references for the basis of the categorization.
Compiled and curated by the experts at Thomson Reuters, a world authority on
the pharmaceutical industry, with extensive participation by key opinion leaders
and stakeholders in research, academia and regulatory bodies.
|
|
|
|
- Discover which biomarkers are associated with a disease
- Determine how trustworthy each biomarker is
- Confirm whether modifying the activity of a target affects a biomarker
- Indicate how safe a drug is
- Find optimum doses
- Decide which biomarkers are appropriate for clinical trials
|
|
